Metformin Tablet, Extended Release
FDA Label NDC 68645-595

29 label sections · Submitted to the FDA by Legacy Pharmaceutical Packaging, Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Legacy Pharmaceutical Packaging, Llc for the product Metformin (NDC 68645-595). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding description, mechanism of action, absorption and bioavailability, distribution, metabolism and elimination, specific populations, indications & usage, contraindications, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Description

Metformin Hydrochloride Extended-Release Tablets, USP


Metformin hydrochloride extended-release tablets, USP are oral antihyperglycemic drugs
used in the management of type 2 diabetes. Metformin hydrochloride, USP (N,Ndimethyl-
monohydrochloride,Imidodicarbonimidic diamide) is not chemically or
pharmacologically related to any other classes of oral antihyperglycemic agents. The
structural formula is as shown:

Metformin hydrochloride, USP is a white or almost white, crystalline powder with a
molecular formula of C4H11N5•HCl and a molecular weight of 165.62. Metformin
hydrochloride is freely soluble in water, slightly soluble in alcohol, practically insoluble in
acetone and in Methylene chloride. The pKa of metformin is 12.4. The pH of a 1%
aqueous solution of metformin hydrochloride is 6.35.


Metformin hydrochloride extended-release tablets, USP contain 500 mg or 750 mg of
metformin hydrochloride as the active ingredient.

Metformin hydrochloride extended-release tablets, USP 500 mg and 750 mg tablets
contain the inactive ingredients hypromellose, magnesium stearate, and polyvinyl
pyrrolidone.


Dissolution Method: Test 10

System Components and Performance - Metformin hydrochloride extended-release

tablets, USP comprises a dual hydrophilic polymer matrix system. Metformin
hydrochloride, USP is combined with a drug release controlling polymer to form an
"inner" phase, which is then incorporated as discrete particles into an "external" phase of
a second polymer. After administration, fluid from the gastrointestinal (GI) tract enters
the tablet, causing the polymers to hydrate and swell. Drug is released slowly from the
dosage form by a process of diffusion through the gel matrix that is essentially
independent of pH. The hydrated polymer system is not rigid and is expected to be
broken up by normal peristalsis in the GI tract. The biologically inert components of the
tablet may occasionally remain intact during GI transit and will be eliminated in the feces
as a soft, hydrated mass.

Mechanism Of Action

Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects (except in special circumstances, see PRECAUTIONS) and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.

Absorption And Bioavailability

Following a single oral dose of Metformin Hydrochloride Extended-Release Tablets, C maxis achieved with a median value of 7 hours and a range of 4 to 8 hours.Peak plasma levels are approximately 20% lower compared to the same dose of metformin hydrochloride tablets, however, the extent of absorption (as measured by AUC) is similar to metformin hydrochloride tablets.

At steady state, the AUC and C maxare less than dose proportional for metformin hydrochloride extended-release tablets within the range of 500 to 2000 mg administered once daily. Peak plasma levels are approximately 0.6, 1.1, 1.4, and 1.8 mcg/mL for 500, 1000, 1500, and 2000 mg once-daily doses, respectively. The extent of metformin absorption (as measured by AUC) from metformin hydrochloride extended-release tablets at a 2000 mg once-daily dose is similar to the same total daily dose administered as metformin hydrochloride tablets 1000 mg twice daily. After repeated administration of metformin hydrochloride extended-release tablets, metformin did not accumulate in plasma.

Within-subject variability in C maxand AUC of metformin from metformin hydrochloride extended-release tablets is comparable to that with metformin hydrochloride tablets.

Although the extent of metformin absorption (as measured by AUC) from the metformin hydrochloride extended-release tablets increased by approximately 50% when given with food, there was no effect of food on C maxand T maxof metformin. Both high and low fat meals had the same effect on the pharmacokinetics of metformin hydrochloride extended-release tablets.

Metabolism And Elimination

Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion. Renal clearance (see Table 1) is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.

Specific Populations

Patients with Type 2 Diabetes

In the presence of normal renal function, there are no differences between single- or multiple-dose pharmacokinetics of metformin between patients with type 2 diabetes and normal subjects (see Table 1) nor is there any accumulation of metformin in either group at usual clinical doses.

The pharmacokinetics of metformin hydrochloride extended-release tablets in patients with type 2 diabetes is comparable to those in healthy normal adults.

Renal Impairment

In patients with decreased renal function (based on measured creatinine clearance), the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased in proportion to the decrease in creatinine clearance (see Table 1: also see also see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, and DOSAGE AND ADMINISTRATION).


Hepatic Impairment

No parmacokinetic studies of metformin have been conducted in patients with hepatic insufficiency (see PRECAUTIONS).


Geriatrics

Limited data from controlled pharmacokinetic studies of metformin hydrochloride tablets in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and Cmax is increased, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function (see Table 1; also see WARNINGS, PRECAUTIONS, and DOSAGE AND ADMINISTRATION). Metformin hydrochloride extended-release tablets treatment should not be initiated in patients ≥80 years of age unless measurement of creatinine clearance demonstrates that renal function is not reduced (see WARNINGSand DOSAGE AND ADMINISTRATION).

Table 1: Select Mean (± S.D.) Metformin Pharmacokinetic Parameters Following Single or Multiple Oral Doses of Metformin Hydrochloride Tablets
Subject Groups: Metformin Hydrochloride Tablet dose a(number of subjects) Cmax b

(mcg/mL)
Tmax c

(hrs)
Renal

Clearance (mL/min)
Healthy, nondiabetic adults:
500 mg single dose (24)1.03 (±0.33)2.75 (±0.81)600 (±132)
850 mg single dose (74)d1.60 (±0.38)2.64 (±0.82)552 (±139)
850 mg three times daily for 19 doses e(9) 2.01 (±0.42)1.79 (±0.94)642 (±173)
Adults with type 2 diabetes:
850 mg single dose (23)1.48 (±0.5)3.32 (±1.08)491 (±138)
850 mg three times daily for 19 dosese (9)1.90 (±0.62)2.01 (±1.22)550 (±160)
Elderly f, healthy nondiabetic adults:
850 mg single dose (12)2.45 (±0.70)2.71 (±1.05)412 (±98)
Renal-impaired adults:
850 mg single dose
Mild (CL crg61-90 mL/min) (5) 1.86 (±0.52)3.20 (±0.45)384 (±122)
Moderate (CL cr31-60 mL/min) (4) 4.12 (±1.83)3.75 (±0.50)108 (±57)
Severe(CL cr10-30 mL/min) (6) 3.93 (±0.92)4.01 (±1.10)130 (±90)

a All doses given fasting except the first 18 doses of the multiple dose studies

b Peak plasma concentration

c Time to peak plasma concentration

d Combined results (average means) of five studies: mean age 32 years (range 23-59 years)

e Kinetic study done following dose 19, given fasting

f Elderly subjects, mean age 71 years (range 65-81 years)

g CLcr = creatinine clearance normalized to body surface area of 1.73 m 2

Gender

Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 diabetes when analyzed according to gender (males = 19, females = 16).

Race

No studies of metformin pharmacokinetic parameters according to race have been performed.

Clinical Studies

Metformin Hydrochloride Extended-Release Tablets

A 24-week, double-blind, placebo-controlled study of metformin hydrochloride extended-release tablets, taken once daily with the evening meal, was conducted in patients with type 2 diabetes who had failed to achieve glycemic control with diet and exercise (HbA1c 7 to 10%, FPG 126 to 270 mg/dL). Patients entering the study had a mean baseline HbA1c of 8% and a mean baseline FPG of 176 mg/dL. After 12 weeks treatment, mean HbA 1c had increased from baseline by 0.1% and mean FPG decreased from baseline by 2 mg/dL in the placebo group, compared with a decrease in mean HbA 1c of 0.6% and a decrease in mean FPG of 23 mg/dL in patients treated with metformin hydrochloride extended-release tablets 1000 mg once daily. Subsequently, the treatment dose was increased to 1500 mg once daily if HbA 1c was ≥7% but <8% (patients with HbA 1c ≥8% were discontinued from the study). At the final visit (24-week), mean HbA 1c had increased 0.2% from baseline in placebo patients and decreased 0.6% with metformin hydrochloride extended-release tablets.

A 16-week, double-blind, placebo-controlled, dose-response study of metformin hydrochloride extended-release tablets, taken once daily with the evening meal or twice daily with meals, was conducted in patients with type 2 diabetes who had failed to achieve glycemic control with diet and exercise (HbA 1c 7 to 11%, FPG 126 to 280 mg/dL). Changes in glycemic control and body weight are shown in Table 2.

Table 2:Summary of Mean Changes from Baseline* in Hb A1c, Fasting Plasma Glucose, and Body Weight at Final Visit (16-week study)
Metformin Hydrochloride Extended–Release TabletsPlacebo
500 mg once Daily1000 mg once Daily1500 mg once Daily2000 mg once Daily1000 mg once Daily
Hemoglobin A1c (%)
Baseline
Change at FINAL VISIT
p-value a
(n=115)
8.2
-0.4
<0.001
(n=115)
8.4
-0.6
<0.001
(n=111)
8.3
-0.9
<0.001
(n=125)
8.4
-0.8
<0.001
(n=112)
8.4
-1.1
<0.001
(n=111)
8.4
0.1
-
FPG (mg/dL)
Baseline
Change at FINAL VISIT
p-value a
(n=126)
182.7
-15.2
<0.001
(n=118)
183.7
-19.3
<0.001
(n=120)
178.9
-28.5
<0.001
(n=132)
181
-29.9
<0.001
(n=122)
181.6
-33.6
<0.001
(n=113)
179.6
7.6
-
Body Weight (lbs)
Baseline
Change at FINAL VISIT
p-value a
(n=125)
192.9
-1.3
NS**
(n=119)
191.8
-1.3
NS**
(n=117)
188.3
-0.7
NS**
(n=131)
195.4
-1.5
NS**
(n=119)
192.5
-2.2
NS**
(n=113)
194.3
-1.8
-

*All patients on diet therapy at Baseline

aAll comparisons versus Placebo

**Not statistically significant

Compared with placebo, improvement in glycemic control was seen at all dose levels of metformin hydrochloride extended-release tablets and treatment was not associated with any significant change in weight (see DOSAGE AND ADMINISTRATION) for dosing recommendations for metformin hydrochloride extended-release tablets.

A 24-week, double-blind, randomized study of metformin hydrochloride extended-release tablets, taken once daily with the evening meal, and metformin hydrochloride tablets, taken twice daily (with breakfast and evening meal), was conducted in patients with type 2 diabetes who had been treated with metformin hydrochloride 500 mg twice daily for at least 8 weeks prior to study entry.

The metformin hydrochloride dose had not necessarily been titrated to achieve a specific level of glycemic control prior to study entry. Patients qualified for the study if HbA 1c was ≤8.5% and FPG was ≤200 mg/dL. Changes in glycemic control and body weight are shown in Table 3.

Table3: Summary of Mean Changes from Baseline* in HbA1c, Fasting Plasma Glucose, and Body Weight at Week 12 and at Final Visit (24-week study)
Metformin Hydrochloride Tablets
500 mg
Twice Daily
Metformin Hydrochloride Extended-Release Tablets
1000 mg
Once Daily
1500 mg
Once Daily
Hemoglobin A1c (%)(n=67)(n=72)(n=66)
Baseline7.066.997.02
Change at 12 Weeks0.140.230.04
(95% CI)(-0.03, 0.31)(0.10, 0.36)(-0.08, 0.15)
Change at FINAL VISIT0.14 a0.270.13
(95% CI)(-0.04, 0.31)(0.11, 0.43)(-0.02, 0.28)
FPG (mg/dL)(n=69)(n=72)(n=70)
Baseline127.2131131.4
Change at 12 Weeks12.99.53.7
(95% CI)(6.5, 19.4)(4.4, 14.6)(-0.4, 7.8)
Change at FINAL VISIT1411.57.6
(95% CI)(7, 21)(4.4, 18.6)(1.0, 14.2)
Body Weight (lbs)(n=71)(n=74)(n=71)
Baseline210.3202.8192.7
Change at 12 Weeks0.40.90.7
(95% CI)(-0.4, 1.5)(0.0, 2)(-0.4, 1.8)
Change at FINAL VISIT0.91.10.9
(95% CI)(-0.4, 2.2)(-0.2, 2.4)(-0.4, 2)

* All patients on metformin hydrochloride tablets 500 mg twice daily at Baseline

a n=68

After 12 weeks of treatment, there was an increase in mean HbA 1c in all groups; in the metformin hydrochloride extended-release tablets 1000 mg group, the increase from baseline of 0.23% was statistically significant (see DOSAGE AND ADMINISTRATION).

Changes in lipid parameters in the previously described placebo-controlled dose-response study of metformin hydrochloride extended-release tablets are shown in Table 4.

Table 4:Summary of Mean Percent Changes from Baseline* in Major Lipid Variables at Final Visit (16-week study)
Metformin Hydrochloride Extended–Release TabletsPlacebo
500 mg once Daily1000 mg once Daily1500 mg once Daily2000 mg once Daily1000 mg Twice Daily
Total Cholesterol (mg/dL)
Baseline
Mean % Change at FINAL
VISIT
(n=120)
210.3
1%
(n=113)
218.1
1.7%
(n=110)
214.6
0.7%
(n=126)
204.4
-1.6%
(n=117)
208.2
-2.6%
(n=110)
208.6
-2.6%
Total Triglyceides (mg/dL)
Baseline
Mean % Change at FINAL
VISIT
(n=120)
220.2
14.5%
(n=113)
211.9
9.4%
(n=110)
198
15.1%
(n=126)
194.2
14.9%
(n=117)
179
9.4%
(n=110)
211.7
10.9%
LDL Cholesterol (mg/dL)
Baseline
Mean % Change at FINAL
VISIT
(n=119)
131
-1.4%
(n=113)
134.9
-1.6%
(n=109)
135.8
-3.5%
(n=126)
125.8
-3.3%
(n=117)
131.4
-5.5%
(n=107)
131.9
-3.2%
HDL Cholesterol (mg/dL)
Baseline
Mean % Change at FINAL
VISIT
(n=120)
40.8
6.2%
(n=108)
41.6
8.6%
(n=108)
40.6
5.5%
(n=125)
40.2
6.1%
(n=117)
42.4
7.1%
(n=108)
39.4
5.8%

*All patients on diet therapy at Baseline

Changes in lipid parameters in the previously described study of metformin hydrochloride tablets and metformin hydrochloride extended-release tablets are shown in Table 5.

Table 5: Summary of Mean Percent Changes from Baseline* in Major Lipid Variables at Final Visit (24 week study)
Metformin Hydrochloride Tablets 500 mg
Twice Daily
Metformin Hydrochloride Extended-Release Tablets
1000 mg Once Daily1500 mg Once Daily
Total Cholesterol (mg/dL)(n=68)(n=70)(n=66)
Baseline199201.9201.6
Mean % Change at FINAL VISIT0.1%1.3%0.1%
Total Triglycerides (mg/dL)(n=68)(n=70)(n=66)
Baseline178169.2206.8
Mean % Change at FINAL VISIT6.3%25.3%33.4%
LDL-Cholesterol (mg/dL)(n=68)(n=70)(n=66)
Baseline122.1126.2115.7
Mean % Change at FINAL VISIT-1.3%-3.3%-3.7%
HDL-Cholesterol (mg/dL)(n=68)(n=70)(n=66)
Baseline41.941.744.6
Mean % Change at FINALVISIT4.8%1%-2.1%

*All patients on metformin hydrochloride tablets 500 mg twice daily at baseline

Contraindications

Metformin hydrochloride extended-release tablets, USP are contraindicated in patients with:

1. Severe Renal Impairment (eGFR below 30mL/min/1.73m2) (see WARNINGS and PRECAUTIONS).

2.Known hypersensitivity to metformin hydrochloride, USP.

3.Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Diabetic ketoacidosis should be treated with insulin.







Adverse Reactions

In A US double blind clinical study of metformin hydrochloride tablets in patients with type 2 diabetes, a total of 141 patients received metformin hydrochloride tablets therapy (up to 2550 mg per day) and 145 patients received placebo. Adverse reactions reported in greater than 5% of the metformin hydrochloride tablets patients, and that were more common in metformin hydrochloride tablets than placebo treated patients, are listed in Table 6.

Table 6: Most Common Adverse Reactions (>5 Percent) in a Placebo-Controlled Clinical Study of Metformin Hydrochloride Tablets Monotherapy*
Diarrhea53.211.7
Nausea/Vomiting25.58.3
Flatulence12.15.5
Asthenia9.25.5
Indigestion7.14.1
Abdominal Discomfort6.44.8
Headache5.74.8

*Reactions that were more common in metformin hydrochloride tablets than placebo treated patients.

Diarrhea led to discontinuation of study medication in 6% of patients treated with metformin hydrochloride tablets. Additionally, the following adverse reactions were reported in ≥1 - ≤5% of metformin hydrochloride tablets patients and myalgia, lightheaded, dyspnea, nail disorder, rash, sweating increased, taste disorder, chest discomfort, chills, flu syndrome, flushing, and palpitation.

In worldwide clinical trials over 900 patients with type 2 diabetes have been treated with metformin hydrochloride extended-release tablets in placebo and active controlled studies. In placebo controlled trails, 781 patients were administered metformin hydrochloride extended-release tablets and 195 patients received placebo. Adverse reactions reported in greater than 5% of the metformin hydrochloride extended release tablets patients, and that were more common in metformin hydrochloride extended-release tablets than placebo treated patients are listed in Table 7.

Table 7: Most Common Adverse Reactions (>5 Percent) in Placebo-Controlled Studies of Metformin Hydrochloride Extended-Release Tablets*
Metformin Hydrochloride Extended-Release Tablets(N=781)

Placebo

(N=195)

Adverse Reactions% of patients
Diarrhea9.62.6
Nausea/Vomiting6.51.5

Diarrhea led to discontinuation of study medication in 0.6% of patients treated with metformin hydrochloride extended-release tablets. Additionally, the following adverse reactions were reported in ≥1 - ≤5% of metformin hydrochloride extended-release tablets patients and were more commonly reported with metformin hydrochloride extended-release tablets than placebo: abdominal pain, constipation, distention abdomen, dyspepsia/heartburn, flatulence, dizziness, headache, upper respiratory infection, taste disturbance.*Reactions that were more common in metformin hydrochloride extended-release tablets than placebo treated patients.

Overdosage

Overdose of metformin hydrochloride has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases (see WARNINGS). Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.

Dosage And Administration

There is no fixed dosage regimen for the management of hyperglycemia in patients with type 2 diabetes with metformin hydrochloride extended-release tablets, USP or any other pharmacologic agent. Dosage of metformin hydrochloride extended-release tablets, USP must be individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended daily doses. The maximum recommended daily dose of metformin hydrochloride extended-release tablets, USP in adults is 2000 mg.

Metformin hydrochloride extended-release tablets, USP should generally be given once daily with the evening meal. Metformin hydrochloride extended-release tablets, USP should be started at a low dose, with gradual dose escalation, both to reduce gastrointestinal side effects and to permit identification of the minimum dose required for adequate glycemic control of the patient.

During treatment initiation and dose titration (see Recommended Dosing Schedule), fasting plasma glucose should be used to determine the therapeutic response to metformin hydrochloride extended-release tablets, USP and identify the minimum effective dose for the patient. Thereafter, glycosylated hemoglobin should be measured at intervals of approximately 3 months. The therapeutic goal should be to decrease both fasting plasma glucose and glycosylated hemoglobin levels to normal or near normal by using the lowest effective dose of metformin hydrochloride extended-release tablets, USP either when used as monotherapy or in combination with sulfonylurea or insulin.

Monitoring of blood glucose and glycosylated hemoglobin will also permit detection of primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication, and secondary failure, i.e., loss of an adequate blood glucose lowering response after an initial period of effectiveness.

Short-term administration of metformin hydrochloride extended-release tablets, USP may be sufficient during periods of transient loss of control in patients usually well-controlled on diet alone.

Metformin hydrochloride extended-release tablets, USP must be swallowed whole and never crushed or chewed.Occasionally, the inactive ingredients of metformin hydrochloride extended-release tablets, USP will be eliminated in the feces as a soft, hydrated mass. (See Patient Informationprinted below.)

Recommendations For Use In Renal Impairment

Assess renal function prior to initiation of metformin hydrochloride extended-release tablets and periodically thereafter.
Metformin hydrochloride extended-release tablets are contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m2.
Initiation of metformin hydrochloride extended-release tablets in patients with an eGFR between 30 to 45 mL/minute/1.73 m2 is not recommended.
In patients taking metformin hydrochloride extended-release tablets whose eGFR later falls below 45 mL/min/1.73 m2, assess the benefit risk of continuing therapy.
Discontinue metformin hydrochloride extended-release tablets if the patients eGFR later falls below 30 mL/minute/1.73 m2 (See WARNINGS and PRECAUTIONS).

Discontinuation For Iodinated Contrast Imaging Procedure

Discontinue metformin hydrochloride extended-release tablets at the time of, or prior to, an iodinated
contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2; in patients with
a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial
iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart metformin
hydrochloride extended-release tablets if renal function is stable.

Spl Patient Package Insert

Patient Information

Metformin Hydrochloride Extended-Release Tablets, USP


Read this information carefully before you start taking this medicine and each time you refill your prescription. There may be new information. This information does not take the place of your doctor’s advice. Ask your doctor or pharmacist if you do not understand some of this information or if you want to know more about this medicine.

What are Metformin Hydrochloride Extended-Release Tablets?

Metformin Hydrochloride Extended-Release Tablets are used to treat type 2 diabetes. This is also known as non-insulin-dependent diabetes mellitus. People with type 2 diabetes are not able to make enough insulin or respond normally to the insulin their bodies make. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems including kidney damage, amputations, and blindness. Diabetes is also closely linked to heart disease. The main goal of treating diabetes is to lower your blood sugar to a normal level.

High blood sugar can be lowered by diet and exercise, by a number of medicines taken by mouth, and by insulin shots. Before you take metformin hydrochloride extended-release tablets, try to control your diabetes by exercise and weight loss. While you take your diabetes medicine, continue to exercise and follow the diet advised for your diabetes. No matter what your recommended diabetes management plan is, studies have shown that maintaining good blood sugar control can prevent or delay complications of diabetes, such as blindness.

Metformin hydrochloride and Metformin hydrochloride extended-release tablets have the same active ingredient. However, metformin hydrochloride extended-release tablets works longer in your body. Both of these medicines help control your blood sugar in a number of ways. These include helping your body respond better to the insulin it makes naturally, decreasing the amount of sugar your liver makes, and decreasing the amount of sugar your intestines absorb. Metformin hydrochloride extended-release tablets do not cause your body to make more insulin. Because of this, when taken alone, they rarely cause hypoglycemia (low blood sugar), and usually do not cause weight gain. However, when they are taken with a sulfonylurea or with insulin, hypoglycemia is more likely to occur, as is weight gain.

Tell your doctor if you are pregnant or plan to become pregnant. Metformin hydrochloride extended-release tablets may not be right for you. Talk with your doctor about your choices. You should also discuss your choices with your doctor if you are nursing a child.

Can Metformin hydrochloride extended-release tablets be used in children?

Metformin hydrochloride extended-release tablets has not been studied in children.

How should I take Metformin hydrochloride extended-release tablets?

Your doctor will tell you how much medicine to take and when to take it. You will probably start out with a low dose of the medicine. Your doctor may slowly increase your dose until your blood sugar is better controlled. You should take metformin hydrochloride extended-release tablets with meals.



Your doctor may have you take other medicines along with metformin hydrochloride extended-release tablets to control your blood sugar. These medicines may include insulin shots. Taking metformin hydrochloride extended-release tablets with insulin may help you better control your blood sugar while reducing the insulin dose.



Continue your exercise and diet program and test your blood sugar regularly while taking metformin hydrochloride extended-release tablets. Your doctor will monitor your diabetes and may perform blood tests on you from time to time to make sure your kidneys and your liver are functioning normally. There is no evidence that metformin hydrochloride extended-release tablets causes harm to the liver or kidneys.

Tell your doctor if you:



• have an illness that causes severe vomiting, diarrhea or fever, or if you drink a much lower amount of liquid than normal. These conditions can lead to severe dehydration (loss of

water in your body). You may need to stop taking metformin hydrochloride extended-release tablets for a short time.

• plan to have surgery or an x-ray procedure with injection of dye (contrast agent). You may need to stop taking metformin hydrochloride extended-release tablets for a short time.

• start to take other medicines or change how you take a medicine. Metformin hydrochloride extended-release tablets can affect how well other drugs work, and some drugs can

affect how well metformin hydrochloride extended-release tablets work. Some medicines may cause high blood sugar.

Metformin hydrochloride extended-release tablets must be swallowed whole and never crushed or chewed.Occasionally, the inactive ingredients of metformin hydrochloride extended-release tablets may be eliminated as a soft mass in your stool that may look like the original tablet; this is not harmful and will not affect the way metformin hydrochloride extended-release tablets works to control your diabetes.

What should I avoid while taking Metformin hydrochloride extended-release tablets?

Do not drink a lot of alcoholic drinks while taking metformin hydrochloride extended-release tablets. This means you should not binge drink for short periods, and you should not drink a lot of alcohol on a regular basis. Alcohol can increase the chance of getting lactic acidosis.

What are the side effects of Metformin hydrochloride extended-release tablets?



• Lactic acidosis. Metformin, the active ingredient in metformin hydrochloride extended-release tablets, can cause a rare but serious condition called lactic acidosis (a

buildup of an acid in the blood) that can cause death. Lactic acidosis is a medical emergency and must be treated in the hospital.

Call your doctor right away if you have any of the following symptoms, which could be signs of lactic acidosis:

• you feel cold in your hands or feet

• you feel dizzy or lightheaded

• you have a slow or irregular heartbeat

• you feel very weak or tired

• you have unusual (not normal) muscle pain

• you have trouble breathing

• you feel sleepy or drowsy

• you have stomach pains, nausea or vomiting

Most people who have had lactic acidosis with metformin have other things that, combined with the metformin, led to the lactic acidosis. Tell your doctor if you have any of the following, because you have a higher chance for getting lactic acidosis with metformin hydrochloride extended-release tablets if you:



• have severe kidney problems, or your kidneys are affected by certain x-ray tests that use injectable dye

• have liver problems

• drink alcohol very often, or drink a lot of alcohol in short-term "binge" drinking

• get dehydrated (lose a large amount of body fluids). This can happen if you are sick with a fever, vomiting, or diarrhea. Dehydration can also happen when you sweat a lot with

activity or exercise and do not drink enough fluids

• have surgery

• have a heart attack, severe infection, or stroke

The best way to keep from having a problem with lactic acidosis from metformin is to tell your doctor if you have any of the problems in the list above. Your doctor may decide to stop your metformin hydrochloride extended-release tablets for a while if you have any of these things.



Other Side Effects. Common side effects of metformin hydrochloride extended-release tablets include diarrhea, nausea, and upset stomach. These side effects generally go away after you take the medicine for a while. Taking your medicine with meals can help reduce these side effects. Tell your doctor if the side effects bother you a lot, last for more than a few weeks, come back after they’ve gone away, or start later in therapy. You may need a lower dose or need to stop taking the medicine for a short period or for good.



About 3 out of every 100 people who take metformin hydrochloride extended-release tablets have an unpleasant metallic taste when they start taking the medicine. It lasts for a short time.



Metformin hydrochloride extended-release tablets rarely cause hypoglycemia (low blood sugar) by themselves. However, hypoglycemia can happen if you do not eat enough, if you drink alcohol or if you take other medicines to lower blood sugar.

General advice about prescription medicines

If you have questions or problems, talk with your doctor or other healthcare provider. You can ask your doctor or pharmacist for the information about metformin hydrochloride extended-release tablets that is written for healthcare professionals. Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Do not use metformin hydrochloride extended-release tablets for a condition for which it was not prescribed. Do not share your medicine with other people.

Dispense with Patient Information available at:
https://granulespharma.com/product/metformin-er-tab-500-750/

Manufactured by:
Granules India Limited
Hyderabad-500 081, India

Manufactured For:

Granules Pharmaceuticals Inc.

Chantilly, VA 20151.

Distributed by:
Wal-Mart
Bentonville, AR 72716


Packaged by:
Legacy Pharmaceutical Packaging, LLC
Earth City, MO 63045


Revision Date: 05/ 2023

How Supplied

Metformin Hydrochloride Extended-Release Tablets, USP 500 mg tablets are white to off-white uncoated, modified capsule shaped tablets debossed with “G7” on one side and plain on the other side.

Unit of Use Bottles of 60 Tablets - 500mg - 68645-595-59

Storage

Store at 20° to 25° C (68° to 77° F); excursions permitted within 15° to 30° C (59° to 86° F). [See USP Controlled Room Temperature.]
Dispense in light-resistant containers.


Dispense with Patient Information available at:
https://granulespharma.com/product/metformin-er-tab-500-750/

Manufactured by:
Granules India Limited
Hyderabad-500 081, India


Manufactured for:
Granules Pharmaceuticals Inc.
Chantilly, VA 20151.


Distributed by:
Wal-Mart
Bentonville, AR 72716


Packaged by:
Legacy Pharmaceutical Packaging, LLC
Earth City, MO 63045

Revision date: May 2023

* Please review the disclaimer below.